NASDAQ:TOCA - Tocagen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.44 -0.46 (-4.65 %)
(As of 05/20/2018 01:48 PM ET)
Previous Close$9.44
Today's Range$9.42 - $9.9804
52-Week Range$8.60 - $17.25
Volume129,727 shs
Average Volume118,922 shs
Market Capitalization$187.97 million
P/E Ratio-3.55
Dividend YieldN/A
BetaN/A

About Tocagen (NASDAQ:TOCA)

Tocagen logoTocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive TOCA News and Ratings via Email

Sign-up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TOCA
CUSIPN/A
Phone858-412-8400

Debt

Debt-to-Equity Ratio0.03
Current Ratio4.56
Quick Ratio5.23

Price-To-Earnings

Trailing P/E Ratio-3.55
Forward P/E Ratio-6.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales4,698.76
Cash FlowN/A
Price / CashN/A
Book Value$3.00 per share
Price / Book3.15

Profitability

EPS (Most Recent Fiscal Year)($2.66)
Net Income$-38,920,000.00
Net Margins-109,579.49%
Return on Equity-57.09%
Return on Assets-44.55%

Miscellaneous

Employees67
Outstanding Shares19,910,000

Tocagen (NASDAQ:TOCA) Frequently Asked Questions

What is Tocagen's stock symbol?

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

How were Tocagen's earnings last quarter?

Tocagen (NASDAQ:TOCA) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. View Tocagen's Earnings History.

When is Tocagen's next earnings date?

Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Tocagen.

What price target have analysts set for TOCA?

2 Wall Street analysts have issued twelve-month price objectives for Tocagen's shares. Their predictions range from $15.00 to $24.00. On average, they anticipate Tocagen's stock price to reach $19.50 in the next year. View Analyst Ratings for Tocagen.

Who are some of Tocagen's key competitors?

Who are Tocagen's key executives?

Tocagen's management team includes the folowing people:
  • Mr. Martin J. Duvall, CEO & Director (Age 56)
  • Dr. Harry E. Gruber, Co-Founder, Pres of Science and Innovation & Director (Age 65)
  • Mr. Thomas E. Darcy, Co-Founder & Director (Age 67)
  • Dr. Asha Das M.D., Sr. VP & Chief Medical Officer (Age 53)
  • Dr. Douglas J. Jolly Ph.D., Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 70)

When did Tocagen IPO?

(TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

Has Tocagen been receiving favorable news coverage?

News headlines about TOCA stock have trended somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tocagen earned a news impact score of 0.01 on Accern's scale. They also assigned press coverage about the company an impact score of 45.81 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Tocagen's major shareholders?

Tocagen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (2.86%), BVF Inc. IL (2.53%), Northern Trust Corp (0.91%), Russell Investments Group Ltd. (0.41%), Victory Capital Management Inc. (0.24%) and Millennium Management LLC (0.17%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.

Which major investors are selling Tocagen stock?

TOCA stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, JPMorgan Chase & Co., Northern Trust Corp and Victory Capital Management Inc.. View Insider Buying and Selling for Tocagen.

Which major investors are buying Tocagen stock?

TOCA stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Millennium Management LLC and Rhumbline Advisers. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.

How do I buy shares of Tocagen?

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tocagen's stock price today?

One share of TOCA stock can currently be purchased for approximately $9.44.

How big of a company is Tocagen?

Tocagen has a market capitalization of $187.97 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.

How can I contact Tocagen?

Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]


MarketBeat Community Rating for Tocagen (TOCA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tocagen (NASDAQ:TOCA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Tocagen in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 106.57%. The high price target for TOCA is $24.00 and the low price target for TOCA is $15.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$23.6667$23.6667$23.6667
Price Target Upside: 106.57% upside112.07% upside112.07% upside112.07% upside

Tocagen (NASDAQ:TOCA) Consensus Price Target History

Price Target History for Tocagen (NASDAQ:TOCA)

Tocagen (NASDAQ:TOCA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018B. RileyInitiated CoverageBuy$15.00HighView Rating Details
7/25/2017Stifel NicolausReiterated RatingBuy$24.00LowView Rating Details
5/15/2017Leerink SwannInitiated CoverageMkt Perform$19.00MediumView Rating Details
5/9/2017Evercore ISIReiterated RatingOutperform$28.00LowView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Tocagen (NASDAQ:TOCA) Earnings History and Estimates Chart

Earnings by Quarter for Tocagen (NASDAQ:TOCA)

Tocagen (NASDAQ:TOCA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.94)
2019 EPS Consensus Estimate: ($2.78)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.57)($0.57)($0.57)
Q2 20182($0.63)($0.59)($0.61)
Q3 20182($0.61)$0.17($0.22)
Q4 20182($0.64)($0.43)($0.54)
Q1 20191($0.74)($0.74)($0.74)
Q2 20191($0.71)($0.71)($0.71)
Q3 20191($0.68)($0.68)($0.68)
Q4 20191($0.65)($0.65)($0.65)

Tocagen (NASDAQ TOCA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018N/AView Earnings Details
5/21/2018N/AView Earnings Details
5/10/2018Q1 2018($0.65)$0.01 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.53)($0.55)$0.01 million$0.01 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.48)($0.50)$0.01 million$0.01 millionViewN/AView Earnings Details
8/9/2017Q2($0.52)($0.56)$0.01 million$0.01 millionViewN/AView Earnings Details
5/23/2017Q1 2017($2.6950)($4.11)$0.01 million$0.01 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Tocagen (NASDAQ:TOCA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Tocagen (NASDAQ TOCA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 32.48%
Insider Trading History for Tocagen (NASDAQ:TOCA)
Insider Trading History for Tocagen (NASDAQ:TOCA)

Tocagen (NASDAQ TOCA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2017Asha DasSVPBuy2,500$10.00$25,000.002,500View SEC Filing  
4/19/2017Harry E GruberInsiderBuy25,000$10.00$250,000.00View SEC Filing  
4/19/2017Mark G FolettaCFOBuy5,000$10.00$50,000.005,000View SEC Filing  
4/19/2017Paul SchimmelDirectorBuy10,000$10.00$100,000.0023,464View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tocagen (NASDAQ TOCA) News Headlines

Source:
DateHeadline
Equities Analysts Issue Forecasts for Tocagens Q2 2018 Earnings (TOCA)Equities Analysts Issue Forecasts for Tocagen's Q2 2018 Earnings (TOCA)
www.americanbankingnews.com - May 18 at 7:30 AM
Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The ...Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The ...
www.prnewswire.com - May 16 at 4:17 PM
B Riley Likes Tocagen On Prospects For Companys Brain Cancer DrugB Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug
finance.yahoo.com - May 16 at 4:17 PM
Tocagen (TOCA) Receives New Coverage from Analysts at B. RileyTocagen (TOCA) Receives New Coverage from Analysts at B. Riley
www.americanbankingnews.com - May 16 at 3:21 PM
Tocagen (TOCA) Raised to Buy at Zacks Investment ResearchTocagen (TOCA) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 16 at 11:05 AM
Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
finance.yahoo.com - May 14 at 10:36 AM
Tocagen (TOCA) to Release Earnings on MondayTocagen (TOCA) to Release Earnings on Monday
www.americanbankingnews.com - May 14 at 1:56 AM
Tocagen (TOCA) Releases Quarterly  Earnings ResultsTocagen (TOCA) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 8:59 PM
Tocagen Reports First Quarter 2018 Financial and Business ResultsTocagen Reports First Quarter 2018 Financial and Business Results
finance.yahoo.com - May 10 at 4:23 PM
Tocagen (TOCA) Downgraded to Hold at Zacks Investment ResearchTocagen (TOCA) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:21 PM
Reader Inquiry: Tocagen Is Looking Cheap But Is It A Buy?Reader Inquiry: Tocagen Is Looking Cheap But Is It A Buy?
seekingalpha.com - May 6 at 9:53 AM
Tocagen (TOCA) to Release Quarterly Earnings on ThursdayTocagen (TOCA) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 4 at 10:12 AM
Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 10Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 10
finance.yahoo.com - May 3 at 4:14 PM
Tocagen inks commercialization deal with ApolloBio in China; shares up 6%Tocagen inks commercialization deal with ApolloBio in China; shares up 6%
seekingalpha.com - April 20 at 4:20 PM
BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater ChinaBRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China
www.reuters.com - April 19 at 9:43 AM
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater ...Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater ...
www.prnewswire.com - April 19 at 9:43 AM
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China RegionTocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region
finance.yahoo.com - April 19 at 9:43 AM
Tocagen (TOCA) Given Average Recommendation of "Buy" by AnalystsTocagen (TOCA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 18 at 1:35 AM
Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American ...Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American ...
www.prnewswire.com - April 16 at 4:14 PM
Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - April 16 at 9:37 AM
This Day That Year: TocagenThis Day That Year: Tocagen
www.nasdaq.com - April 13 at 10:09 AM
Tocagen (TOCA) Upgraded to "Hold" by Zacks Investment ResearchTocagen (TOCA) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 8 at 8:01 AM
Tocagen (TOCA) Upgraded by BidaskClub to BuyTocagen (TOCA) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 26 at 10:59 PM
Tocagen Inc (TOCA) Given Consensus Recommendation of "Buy" by BrokeragesTocagen Inc (TOCA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 24 at 1:44 AM
Tocagen (TOCA) Stock Rating Upgraded by BidaskClubTocagen (TOCA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 17 at 6:22 AM
Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - March 15 at 9:37 AM
Tocagen (TOCA) Upgraded to "Buy" by Zacks Investment ResearchTocagen (TOCA) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 14 at 12:44 PM
Tocagen to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium 2018Tocagen to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium 2018
finance.yahoo.com - March 13 at 10:03 AM
Tocagen Inc Expected to Earn Q1 2018 Earnings of ($0.57) Per Share (TOCA)Tocagen Inc Expected to Earn Q1 2018 Earnings of ($0.57) Per Share (TOCA)
www.americanbankingnews.com - March 12 at 1:21 AM
Tocagen (TOCA) Lifted to Hold at BidaskClubTocagen (TOCA) Lifted to Hold at BidaskClub
www.americanbankingnews.com - March 10 at 4:23 PM
Tocagen (TOCA) Announces  Earnings ResultsTocagen (TOCA) Announces Earnings Results
www.americanbankingnews.com - March 9 at 12:38 AM
Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business ResultsTocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results
finance.yahoo.com - March 8 at 5:05 PM
Tocagen Receives European Medicines Agency Orphan Medicinal Product Designation for Toca 511 & Toca FC for the Treatment of GliomaTocagen Receives European Medicines Agency Orphan Medicinal Product Designation for Toca 511 & Toca FC for the Treatment of Glioma
finance.yahoo.com - March 7 at 9:48 AM
Tocagen (TOCA) Scheduled to Post Earnings on ThursdayTocagen (TOCA) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 2 at 9:30 AM
Tocagen to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress on Thursday, March 8Tocagen to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress on Thursday, March 8
finance.yahoo.com - March 1 at 9:23 AM
Tocagen Inc (TOCA) Receives Consensus Rating of "Hold" from AnalystsTocagen Inc (TOCA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 27 at 1:52 AM
Tocagen (TOCA) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowTocagen (TOCA) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 4:25 PM
Tocagen (TOCA) vs. Aduro BioTech (ADRO) Financial AnalysisTocagen (TOCA) vs. Aduro BioTech (ADRO) Financial Analysis
www.americanbankingnews.com - February 10 at 1:14 AM
Tocagen to Present at Leerink Partners 7th Annual Global Healthcare ConferenceTocagen to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:03 AM
Tocagen (TOCA) Upgraded to "Sell" at ValuEngineTocagen (TOCA) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 11:46 AM
Tocagen Inc (TOCA) Given Consensus Rating of "Hold" by BrokeragesTocagen Inc (TOCA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:34 AM
BidaskClub Downgrades Tocagen (TOCA) to HoldBidaskClub Downgrades Tocagen (TOCA) to Hold
www.americanbankingnews.com - January 31 at 11:02 AM
Brokerages Anticipate Tocagen Inc (TOCA) to Post ($0.53) EPSBrokerages Anticipate Tocagen Inc (TOCA) to Post ($0.53) EPS
www.americanbankingnews.com - January 27 at 9:14 PM
 Tocagen Inc (TOCA) Given $23.67 Average Price Target by Analysts Tocagen Inc (TOCA) Given $23.67 Average Price Target by Analysts
www.americanbankingnews.com - January 20 at 9:34 PM
Tocagen Inc (TOCA) Short Interest UpdateTocagen Inc (TOCA) Short Interest Update
www.americanbankingnews.com - January 14 at 2:34 AM
Contrasting Tocagen (TOCA) & The CompetitionContrasting Tocagen (TOCA) & The Competition
www.americanbankingnews.com - January 6 at 5:02 AM
 Tocagen Inc (TOCA) Receives Consensus Recommendation of "Buy" from Analysts Tocagen Inc (TOCA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 5 at 5:30 AM
Head-To-Head Survey: Tocagen (TOCA) & Its PeersHead-To-Head Survey: Tocagen (TOCA) & Its Peers
www.americanbankingnews.com - December 28 at 3:21 AM
Tocagen (TOCA) vs. Its Rivals Financial ContrastTocagen (TOCA) vs. Its Rivals Financial Contrast
www.americanbankingnews.com - December 28 at 12:16 AM
Analyzing Tocagen (TOCA) and The CompetitionAnalyzing Tocagen (TOCA) and The Competition
www.americanbankingnews.com - December 26 at 1:10 AM

SEC Filings

Tocagen (NASDAQ:TOCA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tocagen (NASDAQ:TOCA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tocagen (NASDAQ TOCA) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.